Biosimilars | Access & Reimbursement | US/EU5 | 2017

The success of biologics will greatly depend on payers because they are the ones who determine which products gain formulary access and preferential reimbursement. Understanding the factors that influence payer decisions regarding biosimilars, particularly their thinking behind reimbursement of recent additions to the market like Pfizer’s Inflectra (infliximab-dyyb) and Celltrion/Mundipharma’s Truxima (rituximab), is critical for successfully managing the launch and marketing of a novel biosimilar. This primary market research was designed to assess payers’ current experience with biosimilars and how they expect to manage biosimilars in the future.

Questions answered:

What are payers’ perspectives on the drivers and barriers to biosimilar uptake?
What factors influence which biosimilars are preferred on formularies in the U.S.?
How do payers choose between multiple biosimilars of the same brand in the EU?
What strategies do payers use to manage biosimilars?
What expectations do payers have for biosimilar discounts?
How would the availability of biosimilars influence the pricing of emerging agents?
Will payer strategies for biosimilars differ between therapeutic specialties?

Key markets covered:

France
Germany
Italy
Spain
United Kingdom
United States

Key companies mentioned:

Amgen
Boehringer Ingelheim
Celltrion
Eli Lilly
Hospira
Janssen
Johnson & Johnson
Merck & Co.
Mundipharma
Mylan
Novartis
Pfizer
Roche
Samsung Bioepis
Sandoz
Sanofi
Teva

Key drugs mentioned:

Aranesp
Avastin
Basaglar
Benepali
Binocrit
Enbrel
Flixabi
Genotropin
Herceptin
Humira
Inflectra
Lantus
Neulasta
Neupogen
Nivestim
Omnitrope
Procrit/Epogen
Remicade
Remsima
Rituxan/MabThera
Truxima
Zarzio/Zarxio

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Biosimilars | Access & Reimbursement | US/EU5 | 2017

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Breast Cancer – Unmet Need – Detailed, Expanded Analysis: Advanced Or Metastatic HER2-Positive Breast Cancer (US/EU)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)

Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Reduced Ejection Fraction (US)